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Abstract
Previous work demonstrated a sexually dimorphic on-
togenic expression of Á-aminobutyric acid receptors
(GABABR) in rat pituitary. As sex steroids determine sex-
specific expression patterns, we now studied the effect
of sex hormones on pituitary GABABR expression.
GABABR subunits, measured by Western blot and by
semi-quantitative RT-PCR and luteinizing hormone (LH),
follicle-stimulating hormone (FSH) and testosterone
measured by RIA were determined in two experimental
designs: First experimental design: 8- and 15-day-old
females (8F, 15F); 8F and 15F treated with 100 Ìg tes-
tosterone propionate (TP) on day 1 of life (8F100TP,
15F100TP), 8- and 15-day-old males (8M, 15M) and 8M
and 15M castrated on day 1 (8MC, 15MC). Second exper-
imental design: 8-day-old female and male animals: 8F,
8F100TP, 8F treated with 1 Ìg/day TP on days 1–4
(8F1TP), 8F treated with the androgen antagonist Flutam-
ide (Flut: 2.5 mg/100 g BW of pregnant mother on days
E17-E23) (8F-Flut), 8M, 8MC, 8M treated with Flut as
above (8M-Flut) and 8MC-Flut. In these animals, in addi-
tion, GABA, glutamate, aspartate and taurine were mea-
sured by HPLC in hypothalami and cortex. In the first set
of experiments, GABAB1R mRNA/protein expression was
higher in 8F than in 15F, 8M or 15M. In 8F100TP,
GABAB1R mRNA/protein decreased to male levels. TP
treatment did not alter GABAB1R expression in 15F.
There was no difference in GABAB1R expression be-
tween 8M and 15M and neonatal castration did not modi-
fy its expression. In the second set of experiments, TP
(1 Ìg) or Flut did not modify GABAB1R in 8F, while 100 Ìg
TP continued to decrease GABAB1R expression. In 8M,
Flut, alone or with castration, increased GABAB1R mRNA/
protein expression to 8F. Hypothalamic GABA content
followed the same pattern as pituitary GABABR expres-
sion in 8-day-old animals, suggesting a cross-regulation.
With regard to hormonal levels, 100 Ìg, but not 1 Ìg TP
altered gonadotropins at 8 days, although both treat-
ments effectively androgenized females as evidenced by
lack of cycling. We conclude that androgens, acting pre-
and postnatally, decrease pituitary GABABR subunit ex-
pression.
Copyright © 2004 S. Karger AG, Basel
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Introduction
Gamma-aminobutyric acid (GABA) participates in the
control of hypophyseal secretion acting in the central ner-
vous system (CNS) and directly on the pituitary [1, 2].
Pituitary GABA derives from tuberoinfundibular GABA,
intermediate pituitary lobe GABAergic axons, other hy-
pothalamic GABAergic systems and local synthesis
[3, 4].
GABA acts on ionotropic GABAA/C and metabotropic
GABAB receptors. GABABRs are G-protein-coupled re-
ceptors, in which heterodimeric assembly of a GABAB(1)
and a GABAB(2) subunit confers functionality [5–7]. Ini-
tially, GABAB(1a) and GABAB(1b) splice variants of the
GABAB(1) gene were isolated [8], additional variants are
proposed [9, 10].
Functional GABABRs are also expressed in peripheral
tissues [11, 12]. We have previously described that pitu-
itary GABABRs are coupled to the same CNS signaling
pathways [13]. In addition, GABABRs participate in the
regulation of prolactin and gonadotropin secretion acting
both centrally and directly on the gland in developing and
adult rats [14–17]. The presence of GABAB receptors in
somatotropes has also been demonstrated [4, 18].
Both GABA and GABA biosynthetic enzymes as well
as GABAA and GABAB receptors display particular on-
togenic distributions in the CNS, including critical areas
involved in pituitary control [19–23]. In addition, GABA
plays an important neurodifferentiative role along devel-
opment [24]. Various ontogenic GABABR expression pat-
terns have been described [21, 25, 26]; in some cases a
switch in subunit expression was observed [26, 27]. Pre-
viously we reported particular pituitary GABABR onto-
genic patterns [28]. GABAB(1a), the main subunit ex-
pressed in the pituitary, decreases throughout postnatal
development in both sexes and is more abundant in
female than in male infantile rats.
Several brain-controlled functions differ between
males and females, the most obvious being those involved
in reproductive physiology [29–31]. Sexually dimorphic
differences in neuronal connections and brain structures
are the result of the irreversible action of gonadal hor-
mones during a sensitive period [31, 32]. In rats, andro-
gens secreted both prenatally by fetal testis (E-18) and ear-
ly postnatally [33] permanently masculinize and defemi-
nize neural substrates, controlling sexually dimorphic
brain functions, behavior and genital morphology [29, 30,
34, 35]. Conversely, steroid effects on female gonadotro-
pin patterns and sexual behavior are primarily postnatal
[31]. These sexually divergent anatomical and behavioral
characteristics are the consequence of changes arising
from turning on or shutting off gene expression, e.g.
reflected by differences in receptor or enzyme levels [36–
38].
Due to the clear sexually dimorphic expression of
GABABR at early stages of development in the pituitary
and to the pivotal role of sex steroids in determining sex-
specific expression patterns, the aim of the present work
was to study the effect of sexual differentiation on
GABABR expression in this gland.
Materials and Methods
Animals
Male and female Sprague-Dawley rats (200–250 g) from the Insti-
tuto de Biologı´a y Medicina Experimental colony were housed in
groups in an air-conditioned room, with lights on from 07.00 to
19.00 h. They were given free access to laboratory chow and tap
water. All studies on animals were performed according to protocols
for animal use, approved by the Institutional Animal Care and Use
Committee (IBYME-CONICET) that follows NIH guidelines.
First Experimental Design
Female rats were mated on proestrus and day 1 of gestation was
considered when a vaginal sperm plug was noted the next day. On the
day of birth (designated day 1) the sex of the pups was determined.
For these studies, 8- and 15-day-old pups were selected because, from
previous observations [28], at these ages we expected to find high
ontogenic levels of GABAB1 receptor expression in both sexes and the
sexual difference in expression levels observed before [28]. In addi-
tion, these ages were selected to be able to use the lowest number of
animals possible, as several pituitaries were necessary for each West-
ern blot sample (see below). Within 24 h of birth, pups were random-
ly assigned to treatment groups. The females were injected subcuta-
neously (s.c.) on the day of birth either with 0.05 ml castor-oil vehicle
(8- and 15-day-old control females: 8F and 15F) or with a single
injection of 100 Ìg of testosterone propionate (TP) in 0.05 ml castor
oil [39] (neonatally androgenized females: 8F100TP and 15F100TP).
Males were either castrated neonatally on day 1 (8MC and 15MC) or
sham castrated (control males: 8M and 15M). Neonatal castration
was performed under cold anesthesia. Pups were kept with their
mothers until the day of the experiment. Animals were killed at 8 or
15 days of age by decapitation, early in the morning (09.00–10.00 h)
to avoid circadian variations. Serum, anterior hypophysis, hypothal-
ami and cortex were collected and frozen at –70°C.
Second Experimental Design
In this case only 8-day-old animals were included, since the first
experimental design showed that by 15 days of age animals had al-
ready attained adult, low levels of expression. Timed pregnant rats
were daily injected s.c. with either 10% ethanol in castor oil (vehicle
control) or Flutamide (Flut: an androgen receptor antagonist, 25 mg/
kg BW adjusted daily based on body weight, prepared by dissolving
the drug first in absolute ethanol, where it dissolved completely, and
then diluting it in castor oil), from day 17 of gestation until the day
before delivery [40]. Within 24 h of birth, the sex of the pups was
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determined. In the case of newborn pups from Flut-treated mothers,
males were not readily distinguishable from females as all had clitoris,
clitoral urethra and nipples. To distinguish between them, application
of manual pressure to the abdomen resulted in immediate and revers-
ible eversion of gubernacular cones, allowing the unequivocal distinc-
tion between male and females [41]. Gubernacular cones are male-
specific, papilla-like structures growing in the abdominal inguinal
region towards the end of prenatal life and are a prerequisite for post-
natal testis descent; their development is not altered by flutamide
treatment [41]. Newborn females, from vehicle-injected mothers,
were injected s.c. with TP on day 1of life (single dose of 100 Ìg in
0.05 ml castor oil: 8F100TP), or received one daily injection of either
1 Ìg TP in 0.05 ml castor oil (8F1TP) or vehicle (8F: controls) on
postnatal days 1–4 following the androgenization protocol described
by McDonald and Doughty [42]. Newborn female pups from Flut-
injected mothers were left without further treatment (8F-Flut). New-
born males from vehicle or Flut-injected mothers were either castrated
(8MC or 8MC-Flut) or sham castrated (8M and 8M-Flut) on the day of
birth. Animals were killed at 8 days of age by decapitation, early in the
morning, to avoid circadian variations. Serum, anterior hypophysis,
hypothalami and cortex were collected and frozen at –70°C.
Group of control females (F), females injected with either 100 Ìg
TP (F100TP) or 1 Ìg TP (F1TP), as in the second experimental
design, were left to grow and were weaned on day 21. Beginning on
day 28 of age they were weighted and examined daily for vaginal
opening. No animals belonging to the F100TP group showed vaginal
opening. From days 40 through 75 of age, vaginal smears were
obtained from both F1TP and F at least six times per week. Finally,
animals from each treatment condition were killed by decapitation,
at approximately 75 days of age, either early in the morning, around
9.00 a.m. or later in the afternoon, around 5.00 p.m. (F were killed on
proestrous) and trunk blood was collected.
Regular cycles were defined as the occurrence of 3 consecutive
4–5-day cycles. The beginning of regular cycles in control females (F)
was detected from 50 through 60 days of life. Anestrous, an indica-
tion of the loss of the capacity of cyclic release of gonadotropins in
amounts enough for ovulation, was defined as the presence of corni-
fied smears, similar to estrous vaginal smears (squamous epithelial
cells), during at least fifteen consecutive days. ‘Pin hole’ vaginal
opening [42] was defined as the occurrence of a little orifice either not
allowing or allowing partial intrusion of the plastic pipette to take a
sample of vaginal fluid.
Drugs
Testosterone propionate and flutamide (2-methyl-N-[4-nitro-3-
(trifluoromethyl)-phenyl]propanamide), an androgen receptor antag-
onist, were acquired from Sigma-Aldrich, St. Louis, Mo., USA.
Membrane Preparation
Anterior pituitaries were collected and the membrane fraction
was isolated as previously described [28]. Briefly, pituitaries (10
pituitaries for each 8-day-old sample and 7 for each 15-day-old sam-
ple) were homogenized in 10 vol of ice-cold 0.32 M sucrose, contain-
ing 1 mM MgCl2 and 1 mM K2HPO4, with a glass/teflon homogeniz-
er. Membranes were centrifuged at 750 g, the pellet was resuspended
and the centrifugation repeated. The supernatants were pooled and
centrifuged at 18,000 g for 15 min. The pellet was osmotically
shocked, centrifuged at 39,000 g, resuspended in 50 mM Tris-HCl,
2.5 mM CaCl2, pH 7.4 (10 vol/g of original tissue). Membranes were
frozen at –70°C.
Western Blot Analysis
Western blot analysis of GABABR subunits were performed as
described by Bianchi at al [28]. Briefly, 40 Ìg of pituitary membranes
proteins measured by the Lowry method were subjected to 8% SDS-
PAGE. Proteins were transferred onto nitrocellulose by standard wet
elctrophoretic transfer in a 0.2 M phosphate buffer. Blots were
blocked in NETG buffer (150 mM NaCl; 5 mM EDTA; 50 mM Tris-
HCl, pH 7.4; 0.05% Triton X-100; 0.25% gelatin) for 45 min at room
temperature. GABAB1 subunit was detected by incubating for 45 min
at room temperature with the antibody Ab174.1 (1:3,000), developed
by Dr. Bettler [5], directed against the C-terminal epitopes of
GABAB(1a/b), labeling proteins of 120 and 100 kDa, respectively. In
all immunoblotting experiments, a monoclonal antibody directed
against ·-syntaxin (1:3,000) was used to ensure comparable protein
load. Secondary antibody was peroxidase coupled (1:3,000). Blots
were washed following each antibody incubation for 50 min with
NETG. Detection of the antibody was performed using enhanced
chemiluminescence Western blot analysis system (Western Blotting
Chemiluminescence Luminol Reagent, Santa Cruz Biotechnology,
Inc., Santa Cruz, Calif., USA). Quantification of immunoblots was
performed with Imagequant soft.
Amino Acidic Neurotransmitter Determination by HPLC
Glutamate, GABA, aspartate and taurine were determined in
hypothalami (limited anteriorly by the optic chiasma, laterally by the
hypothalamic fissures, posteriorly by the mammillary bodies and in
depth by the subthalamic sulcus, and including the preoptic-supra-
chiasmatic area [43] and frontoparietal cortex from: 8F, 8F1TP,
8F100TP, 8F-Flut, 8M, 8MC, 8M-Flut and 8MC-Flut. Amino acids
were determined using the procedure previously described by Saller
and Czupryna [44] with minor modifications. An HPLC system,
which consisted of a Model 125 Programmable Solvent Module
(Beckman Instruments, Fullerton, Calif., USA), a 5-Ìm, 25 cm !
4.6-mm Ultrasphere® ODS reversed-phased column (Beckman), a
Model 166 Programmable UV Detector Module (254 nm) (Beck-
man) and System Gold® software (Beckman) was used. The mobile
phase consisted of a water-acetonitrile mixture (82:18, v/v) contain-
ing 0.15% (v/v) phosphoric acid. Final treatment of standards and
samples consisted of: the dansyl derivatives, placed in 1.5-ml micro-
fuge tubes, were evaporated to dryness in a Savant Speed-Vac con-
centrator (Savant Instruments, Holbrook, N.Y., USA) and the dried
residues were vigorously resuspended in 200 Ìl of mobile phase using
a vortex mixer, placed in a ultrasonic bath and finally centrifuged at
13,000 g for 3 min to remove particulate matter before injecting
20-Ìl aliquots of the supernatants into the HPLC system.
Hormone Dosage
Serum LH and FSH were determined by RIA using kits obtained
through NHPP, NIDDK and Dr. Parlow. Results were expressed in
terms of RP3 rat LH and FSH standards. Assay sensitivities were
0.015 ng/ml for LH and 0.1175 ng/ml for FSH. Intra- and inter-assay
coefficients of variation for LH were 7.2 and 11.4%, respectively,
and for FSH 8.0 and 13.2%, respectively. Serum testosterone was
determined by RIA using a specific antiserum kindly provided by
Dr. G.D. Niswender, after ethyl-ether extraction. Labeled hormone
was purchased from New England Nuclear. Assay sensitivity: lowest
point in the testosterone standard curve was 12.5 pg, the lowest
detectable concentration when extracting 150 Ìl serum was 208.3 pg/
ml. Intra- and interassay coefficients of variation were 7.8 and
12.3%, respectively.
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Fig. 1. Validation of semiquantitative RT-
PCR for GABAB1 receptor subunit and ß-
actin. Total RNA from pituitaries was re-
verse transcribed. A linear relationship was
observed between the optical density of PCR
products and (a) Ìg of RNA; (b) number of
cycles when 0.5 Ìg of RNA was reverse tran-
scribed, and (c) Ìl of cDNA when 0.5 Ìg of
RNA was reverse transcribed and amplified
at 36 and 20 cycles for GABAB1 receptor
subunit and ß-actin, respectively. A repre-
sentative curve is shown in each case.
Total RNA Preparation and RT-PCR Analyses
Total RNA was obtained using the Trizol RNA isolation reagent
(Invitrogen, Calif., USA) from fresh rat pituitaries from the same
experimental groups. In the second experimental design, 8-day-old
females treated with 1 Ìg TP on days 1–4 and 8-day-old females
treated in utero with Flut were not included, as these treatments did
not modify GABABR expression evaluated by Western Blots or hor-
mone levels (see ‘Results’). The RNA concentration was determined
based on absorbance at 260 nm and its purity was evaluated by the
ratio of absorbencies at 260 nm/280 nm (11.8). RNA quality was
assessed running random samples on denaturated gels. RNAs were
kept frozen at –70 °C until analyzed.
Total RNA (0.5 Ìg) was reverse-transcribed into cDNA using
MMLV (Invitrogen) according to the manufacturer’s instructions,
primed with oligo(dT)15 (Biodynamics SRL, Argentina). In all RT
reactions a negative control, lacking MMLV, was included.
PCR (2 Ìl of RT reaction) consisted of a 5-min hot start step
followed by 36 cycles (GABAB1) or 20 cycles (ß-actin) of denaturation
at 94°C for 1 min, annealing at 55 °C for 1 min and extension at
72°C 1 min; with a final extension for 10 min at 72°C after the last
cycle. PCR amplifications were carried out using Taq DNA poly-
merase (Invitrogen-Life Technologies, USA) and specific oligonu-
cleotide primers which were chosen to encompass exon-intron
boundaries to avoid possible genomic DNA contamination. PCR
reactions were performed following the Taq DNA polymerase manu-
facturer’s instructions. The primers for GABAB1 subunit (Bio Syn-
thesis, USA) did not distinguish between the splice variants
GABAB(1a) and GABAB(1b) and were synthesized based on the
sequences described by Schuler et al. [45], amplifying a theoretical
fragment of 254 bp from mRNA and of 690 bp from genomic DNA.
The primers for ß-actin (Invitrogen-Life Technologies, USA) were
synthesized following a published sequence [46]: forward: 5)-GGA-
AATCGTGCGTGACAT-3); reverse: 5)-GGAAGGTGGACAGTG-
AGG-3), amplifying a fragment of 440 bp from mRNA and 652 bp
for genomic DNA. To ensure accuracy of the PCR, samples were run
without template (control). Finally, the reactions were electropho-
resed on 1.5% agarose gels and stained with ethidium bromide. The
gels were exposed to UV with a white/UV ultraviolet transiluminator
(UVP Laboratory Products) and the images quantified using the
Scion Images NIH software.
To evaluate levels of GABAB1 mRNA expression in pituitaries
from different treatment groups, PCRs were performed using the
expression of ß-actin mRNA as control of the variation in the RNA
concentration in RT reaction. To validate the assay for GABAB1
measurements, different amounts of total RNA were reverse tran-
scribed, and aliquots were amplified with the specific primers for
GABAB1 or ß-actin mRNA for different number of cycles. A linear
relationship between the Ìg of RNA and PCR products was obtained
(fig. 1a). As a result, 0.5 Ìg total RNA was used in RT reactions. A
linear relationship between the PCR products and cycle number was
also obtained when 0.5 Ìg total RNA was used in RT (fig. 1b). As a
result, 36 and 20 amplification cycles were selected for GABAB1 and
ß-actin, respectively. Finally, a linear relationship in detection was
also attained when different amounts of cDNA, obtained from 0.5 Ìg
reverse-transcribed RNA, were subjected to PCR (fig. 1c).
Statistical Analysis
Differences in GABABR subunit expression, GABAB1 mRNA
levels, neurotransmitters levels, hormonal levels and puberty param-
eters were analyzed by either one-way or two-way analysis of vari-
ance (ANOVA) followed by Tukey HSD for unequal N test (Statisti-
ca v 5). Data were transformed when the test for homogeneity of
variances so required. In the case of LH measurements in 8-day-old
animals, no transformation of data allowed compliance to the homo-
geneity of variances tests, therefore data were analyzed by Kruskal-
Wallis non-parametric ANOVA test. Correlations were analyzed
with Statistica v 5. In all cases, results were considered significant
when p ! 0.05.
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Fig. 2. GABAB1 receptor subunit expression in anterior hypophysis
from 8- and 15-day-old animals under different treatments deter-
mined by Western blot with specific antisera. For this and the follow-
ing figures: 8F and 15F: 8- and 15-day-old control females (injected
with castor oil), 8F100TP and 15F100TP: 8- and 15-day-old females
treated with 100 Ìg of TP on the day of birth, 8M and 15M: sham
castrated control males and 8MC and 15MC: 8- and 15-day-old
males castrated on the day of birth. Upper panel: Representative
Western blot for GABAB1a and GABAB1b subunit and ·-syntaxin
expression. Ctx = Cortex membranes used as positive controls;
MW = molecular weight markers. Lower panel: Data are expressed as
the ratio of each GABAB1 subunit expression to ·-syntaxin expres-
sion. Number of samples per group: 8F = 10, 8F100TP = 7, 15F = 6,
15F100TP = 5, 8M = 11, 8MC = 11, 15M = 5, 15MC = 5. Results
were analyzed by two-way ANOVA: interaction: n.s., indicating that
both subunits follow the same expression pattern among groups; fac-
tor subunit: p ! 0.001, indicating that GABAB1a levels are higher than
GABAB1b levels; factor treatment: p ! 0.02 or less; a = different from
control females (8F); * = different from GABAB1a levels.
Results
Effects of Neonatal Female Androgenization and Male
Castration on GABAB1 Expression and Hormone
Levels
In agreement with our previous results, both
GABAB1R subunit proteins, GABAB(1a) and GABAB(1b),
were expressed in male and female anterior pituitary
glands from 8- and 15-day-old animals (fig. 2), the former
being significantly more abundant in all groups and both
splice variants following parallel patterns of expression
among treatment groups. Besides, the expression of
GABAB(1) subunits was maximal in pituitary membranes
from 8-day-old females (8F), confirming that their expres-
sion decreases with age and that it is higher in females
than in males (8M) at early stages of development. No
differences between sexes were observed in animals at 15
days of age (15F and 15M). Neonatal androgenization
(100 Ìg TP: 8F100TP) significantly decreased the
GABAB(1) subunit expression in 8-day-old female rat pitu-
itary membranes reaching levels similar to those observed
in control males. On the other hand, neonatal male castra-
tion (8MC) did not significantly alter GABAB(1) expres-
sion. To determine if these treatments also affected the
expression of the GABAB1 subunit mRNA, semiquantita-
tive RT-PCR were carried out from pituitaries belonging
to the same groups, obtaining similar results (fig. 3).
The neonatal treatments produced alterations in go-
nadotropin titers, which confirmed their efficacy. Neona-
tal testosterone treatment in females reduced serum LH
(fig. 4) either to control 8-day-old male levels (LH (ng/ml):
8F: 1.13 B 0.09 vs. 8F100TP: 0.48B 0.06 or 8M: 0.55 B
0.04, p ! 0.01) or to even lower levels in 15-day-old rats
(LH (ng/ml): 15F: 1.14 B 0.16 vs. 15F100TP: 0.28 B
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Fig. 3. GABAB1 receptor subunit mRNA expression in anterior
hypophysis of 8- and 15-day-old animals under different treatments
determined by semiquantitative RT-PCR. Upper panel: Representa-
tive RT-PCR gel for GABAB1 subunit and ß-actin expression. Lower
panel: Data are expressed as the ratio of GABAB1 subunit expression
to ß-actin expression. AU = Arbitrary units. Results were analyzed by
two-way ANOVA taking as factors age and treatments, interaction:
p ! 0.001, * p ! 0.001; different from all the other groups. Number
of cases per group: 8F = 5, 8F100TP = 5, 15F = 6, 15F100TP = 5,
8M = 4, 8MC = 5, 15M = 6, 15MC = 4.
Fig. 4. Gonadotropin serum levels in 8- and 15-day-old animals
under different treatments. Upper panel: LH (ng/ml); lower panel
FSH (ng/ml). Data (n = 15–20 animals per group) were analyzed by
two-way ANOVA taking as factors age and treatments; interaction:
p ! 0.001; a different from 8-day-old control females, b different from
15-day-old control females, c different from 8-day-old control males,
d different from 15-day-old control males, * different from 8-day-old
animals in the same group.
Fig. 5. Testosterone serum levels in 8- and 15-day-old animals under
different treatments. Data (n = 15–20 animals per group) were ana-
lyzed by two-way ANOVA taking as factors age and treatments;
interaction: n.s., factor age: p ! 0.001, factor treatments: p ! 0.001 or
less; a = different from control females, b = different from control
males.
0.05 vs. 15M: 0.52 B 0.05, p ! 0.01). In contrast, neona-
tally castrated males showed a very significant increase in
LH at both ages (LH (ng/ml): 8MC: 2.70 B 0.29 and
15MC: 17.58 B 1.24, p ! 0.01). LH titers in castrated
males were significantly higher than in control females.
Moreover, the increase in 15-day-old castrated males was
considerably more robust than in 8-day-old castrated
males. With regard to FSH serum levels (fig. 4), similar
results were obtained.
When analyzing testosterone (fig. 5), male levels were
significantly higher than in females, as expected (T (pg/
ml): 8M: 402.3 B 39.8 vs. 8F: 267.3 B 17.6, p ! 0.01). No
differences between ages within each group were ob-
served. Besides, the neonatally castrated males (T (pg/ml):
8MC: 267.7 B 21.9) presented female testosterone levels,
whereas androgenized females (T (pg/ml): 8F100TP:
540.1 B 72.2) presented male levels, thus displaying ele-
vated testosterone even 14 days after TP administration.
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Fig. 6. GABAB1 receptor subunit expression in anterior hypophysis
from 8-day-old animals under different treatments determined by
Western blot with specific antisera. For this and the following figures:
8F: 8-day-old control females, 8F1TP: 8-day-old females injected
with 1 Ìg TP on days 1–4 of life, 8F100TP: 8-day-old females treated
with 100 Ìg of TP on the day of birth, 8F-Flut: 8-day-old female pups
from flutamide-injected mothers, 8M: 8-day-old control males,
8MC: 8-day-old males castrated on the day of birth, 8M-Flut: 8-day-
old males from flutamide-injected mothers, 8MC-Flut: 8-day-old
males from flutamide-injected mothers and castrated on the day of
birth. Upper panel: Representative Western blot for GABAB1a and
GABAB1b subunit and ·-syntaxin expression. Ctx = Cortex mem-
branes used as positive controls; MW = molecular weight markers.
Lower panel: Data are expressed as the ratio of GABAB1 subunit
expression to ·-syntaxin expression. Number of samples per group:
8F = 12, 8F1TP = 6: 8F100TP = 12, 8F-Flut = 6, 8M = 12, 8MC = 12,
8M-Flut = 6 and 8MC-Flut = 10. Results were analyzed by two-way
ANOVA: interaction: n.s., indicating that both splice variants follow
the same pattern of expression; factor subunit: p ! 0.001, indicating
that GABAB1a is always more abundant than GABAB1b; factor treat-
ment: p ! 0.001 or less; a = different from 8F, b = different from
8F1TP, c = different from 8F-Flut, d = different from 8M-Flut, e =
different from 8MC-Flut, f = different from 8F100TP, g = different
from 8M, h = different from 8MC.
Effects of Male in utero Flutamide Treatment and
Low-Dose Female Testosterone Administration on
Sexual Differentiation of GABAB Receptor Subunit
Expression and Hormone Levels
As no differences in the expression of GABABR sub-
units were observed in anterior pituitary membranes of
15-day-old animals, in further experiments only 8-day-old
animals were used.
Although treatment of females with 100 Ìg TP on the
day of birth induced a decrease in pituitary GABAB(1) sub-
units expression to male levels at 8 days of age, we could
not discriminate between an organizational or activation-
al effect of the steroid since testosterone serum levels were
still high at sacrifice. On the other hand, the fact that no
increase in GABAB subunits expression was observed in
8-day-old neonatally castrated males may have been due
to incomplete central nervous system defeminization as
the result of intrauterine testosterone imprinting on day
18 of gestation.
Therefore, in order to distinguish between a masculin-
izing effect and a hormonal effect of testosterone, new-
born females were treated with a much lower dose andro-
genization protocol (1 Ìg TP s.c. during 4 consecutive
days, starting on the day of birth). Furthermore, to sup-
press intrauterine testosterone imprinting, timed preg-
nant rats were injected with Flut from day 17 of gestation
until the day before of delivery.
Again in these experimental groups both splice vari-
ants of the GABAB1R were expressed in a parallel way in
all treatment groups, being GABAB1a always more abun-
dant than GABAB1b. The new, low-dose androgenization
protocol did not modify the GABAB1R subunit protein
expression, their levels being similar to 8-day-old females
and significantly higher than 8-day-old males (p ! 0.05),
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Fig. 7. GABAB1 receptor subunit mRNA expression in anterior
hypophysis of 8-day-old animals under different treatments deter-
mined by semiquantitative RT-PCR. Upper panel: Representative
RT-PCR gel for GABAB1 subunit and ß-actin expression. Lower
panel: Data are expressed as the ratio of GABAB1 subunit expression
to ß-actin expression. Results were analyzed by one-way ANOVA.
p ! 0.001; a = different from 8F, b = different from 8M, c = different
from 8MC. Number of cases per group: 8F = 5, 8F100TP = 5, 8M =
4, 8MC = 5, 8M-Flut = 4 and 8MC-Flut = 4.
Fig. 8. Gonadotropin serum levels in 8-day-old animals under differ-
ent treatments. Upper panel: LH (ng/ml), lower panel FSH (ng/ml).
For LH data were analyzed by a non-parametric ANOVA test, p !
0.001; a = different from 8F, b = different from 8F100TP, c = differ-
ent from 8M, d = different from 8M-Flut. For FSH, data were ana-
lyzed by one-way ANOVA, p ! 0.001; a = different from 8F, b =
different from 8M. n = 15–20 animals per group.
Fig. 9. Testosterone serum levels in 8-day-old animals under differ-
ent treatments. Data (n = 15–20 animals per group) were analyzed by
one-way ANOVA, p ! 0.001; a = different from 8F, b = different
from 8M.
while the higher dose continued to be effective (8F100TP)
(fig. 6). In 8-day-old male pituitary membranes from ani-
mals exposed in utero to Flut, a significant increase in
GABAB(1) subunit levels could be observed (8M-Flut vs.
8M, p ! 0.05). In addition, males, in which testosterone
had not exerted its action during both periods of sexual
differentiation (8MC-Flut), displayed higher GABAB(1)
subunits expression than 8M and also statistically higher
than 8MC (8MC-Flut vs. 8MC, p ! 0.05). On the other
hand, prenatal Flut treatment did not alter GABABR sub-
units expression in 8-day-old females (fig. 6). RT-PCR
confirmed these results at mRNA level (fig. 7).
To corroborate the effectiveness of the treatments
gonadotropin serum levels in the different animal groups
were analyzed. Gentle androgenization (8F1TP) did not
induce any alteration in either FSH or LH titers at the
time of sacrifice (fig. 8) (LH (ng/ml): 8F: 2.00 B 0.18 vs.
8F1TP: 2.59 B 0.24, n.s.). Males prenatally exposed to
Flut showed an intermediate level, between control male
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Fig. 10. Glutamate, GABA, aspartate and
taurine levels (Ìmol/g of tissue) in brain cor-
tex form 8-day-old animals under different
treatments; n = 6–11 animals per group.
Data were analyzed by one-way ANOVA,
being nonsignificant for the 4 neurotrans-
mitters analyzed.
and female values, for both gonadotropins (LH (ng/ml):
8M: 0.97 B 0.08 vs. 8M-Flut: 1.81 B 0.21, n.s.). Flut-
treated neonatally castrated males presented similar go-
nadotropin patterns to castrated males (LH (ng/ml):
8MC-Flut: 4.44 B 0.35 vs. 8MC: 4.01 B 0.35, n.s.). Flut
treatment did not modify serum gonadotropins in control
females.
Serum testosterone in females submitted to the low
dose androgenization protocol (fig. 9), still presented ele-
vated titers of this hormone at 8 days of age, not differing
from 8F100TP and 8M (T (pg/ml): 8F1TP: 520.5 B 90.9
vs. 8F100TP: 647.1 B 144.2 vs. 8M: 453.1 B 48.8, n.s.).
With regard to prenatally Flut-treated animals, 8M-Flut
showed control male testosterone levels and 8MC-Flut
had titers similar to those of castrated male (8MC) (T (ng/
ml): 8M-Flut: 415.0B 37.8 vs. 8MC-Flut: 256.8 B 19.7
vs. 8MC: 243.3 B 15.6, p ! 0.01). Flut treatment did not
alter this hormone in females.
Effects of Perinatal Sex Hormone Manipulation on
Neurotransmitter Levels
GABA has been shown to modulate the expression of
its own receptors in the CNS [47]. Therefore, we evaluat-
ed GABA and glutamate (its biosynthetic precursor) in
the same 8-day-old groups in the hypothalamus, an area
critically involved in the control of pituitary function and
in cortex, selected as a control area. In addition, taurine
and aspartate were evaluated to determine specificity of
effects.
In cortex, no differences in taurine, aspartate, gluta-
mate or GABA were observed among any experimental
groups (8F, 8F1TP, 8F100TP, 8F-Flut, 8M, 8MC, 8M-
Flut and 8MC-Flut) (fig. 10). In contrast, glutamate levels
in the hypothalamus were significantly lower in all male
groups, regardless of treatments, than in control females
(fig. 11). Surprisingly, Flut-treated females showed low
glutamate levels as well (p ! 0.05 with respect to control
females), similar to male titers. Interestingly, hypothalam-
ic GABA levels in the different groups showed the same
pattern as pituitary GABABR expression (fig. 11). Control
female GABA levels were higher than control male levels
and 100 Ìg TP in females, but not 1 Ìg TP, decreased
them to control male levels. In addition, Flut plus castra-
tion increased male GABA to control female levels. A pos-
sible relationship between hypothalamic GABA levels
and pituitary GABABR expression is suggested by our
results. In contrast, taurine and aspartate showed similar
levels in the hypothalami of the different groups (fig. 11).
Effect of Androgenization Protocols on the
Hypothalamic-Pituitary-Ovarian Axis
With the purpose of corroborating the effects of the dif-
ferent testosterone treatments on sexual differentiation, a
group of female rats of each group was allowed to reach
adulthood, studying different parameters along their de-
velopment (table 1).
First, the day of vaginal opening was registered. In
females that had been injected with 1 Ìg TP for 4 consecu-
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Fig. 11. Glutamate, GABA, aspartate and
taurine levels (Ìmol/g of tissue) in hypothal-
ami from 8-day-old animals under different
treatments; n = 6–11 animals per group.
Data were analyzed by one-way ANOVA:
p ! 0.01 for glutamate and GABA. a p ! 0.05
or less vs. 8F; b p ! 0.05 vs. 8M.
Table 1. Puberty and cyclicity parameters in control and testosterone-treated adult female rats
Adult
females
Day
of VO
BW at VO
g
BW on
day 34
Estrous cycles
at adulthood
LH, ng/ml
AM PM
FSH, ng/ml
AM PM
Control 38B1 112.6B3.7 94.4B1.9 85% regular 3.6B0.6 23.4B10.6a 4.7B0.5 8.0B1.5b
1TP 34B1* 92.1B3.5* 92.1B3.5 100% anestrus 6.1B1.2 7.7B1.0 8.9B1.6 15.5B2.8
100TP NO – 98.0B3.0 – 4.8B0.7 5.2B1.0 10.9B1.1 12.7B2.7
Adult female rats, belonging to the second experimental design (Materials and Methods) evaluated at the end of puberty and in adulthood.
VO = Vaginal opening; BW = body weight; adult females 1TP = VO as pinhole.
* p ! 0.05, different from controls.
a Different from AM levels; b FSH (AM and PM) levels different from 1TP and 100TP.
tive days (F1TP), vaginal opening occurred on 34 B 1
days of age, significantly earlier than in control females
(p ! 0.05). This difference was not due to a difference in
body weight at this age. In contrast, females that received
a single injection of 100 Ìg TP on the day of birth
(F100TP) did not display vaginal opening until day 75 of
age (when the experiment ended). Second, estrous cycles
were followed after vaginal opening. While the 85% of
control females (F) showed regular cycles, none of the
F1TP females cycled (100% anestrous).
Finally, serum gonadotropins in these animals were
analyzed. As expected, control females presented a signifi-
cant increase in LH levels in the proestrous afternoon
while no differences in either F1TP or F100TP LH titers
between morning and afternoon were observed. With
regard to serum FSH, F1TP and F100TP had significant
higher levels than control females (p ! 0.02) at adulthood.
Discussion
We have previously described a clear sexually dimor-
phic expression pattern for adenohypophyseal GABABRs
at early stages of development. GABAB(1) subunit de-
creases with age in both sexes, being significantly higher
in females than in males at 4 and 12 days of age [28]. In
rats there is a sensitive developmental period during
which sexual differentiation of neural substrates proceeds
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irreversibly under the influence of gonadal hormones. This
period starts a few days before birth and ends approximate-
ly 10 days thereafter [48]. Perinatal alterations in the
endogenous gonadal hormone levels induce changes in sex-
ually dimorphic physiologic, neuroanatomic, molecular
and behavioral characteristics, independently of the genet-
ic sex of the animals [38, 48–50]. Similar data were
obtained after neonatal exposure to stress [51].
In consequence, we evaluated GABABR subunit expres-
sion in neonatally androgenized female and castrated male
pituitaries at 8 and 15 days of age in comparison to con-
trols. In agreement with our previous results [28], expres-
sion levels were higher in 8-day-old than 15-day-old
females or 8-day-old males. At 15 days of age, no sexual
differences in GABABRs were evident. Sexual differences
may be manifested after the critical period of hormonal
action has elapsed and high steroid levels are no longer
present [52, 53], as in sexual differences in gonadotropin
secretion [30]. In contrast, many characteristics cannot be
differentiated by sex in adulthood because these sex differ-
ences are present only transiently during development [32,
54]. For example, around birth, male rats express much
higher levels of progesterone receptor in the medial preop-
tic area than do females; this sex difference starts to disap-
pear once the ovaries become active [55]. GABABR gene
expression exhibits similar characteristics.
Neonatal female androgenization reduced GABABR
expression to male levels, while neonatal male castration
did not induce significant effects. To corroborate the
effectiveness of treatments, gonadotropins and testoster-
one were measured, since both parameters are sexually
dimorphic [56]. Indeed, gonadotropins are higher in fe-
males than in males at 8 and 15 postnatal days, FSH also
being higher in 15-day-old than in 8-day-old females [30,
56]. Females treated neonatally with 100 Ìg TP showed
male gonadotropin patterns, while neonatally castrated
males showed increased gonadotropin secretion, even
higher than control females. This may be due to the lack
of negative feedback action of circulating steroids after
castration. Moreover, in 15-day-old orchidectomized
males, levels were significantly higher than in 8-day-old
castrated males. It has been demonstrated that hypotha-
lamic GnRH increases along development attaining adult
levels in males at 30 days of age [57]. In addition, days
12–18 of postnatal development are characterized in
females by high FSH, sporadic spikes of LH and a high
sensitivity to GnRH [30, 56, 58]. In contrast, LH and
FSH, as well as pituitary GnRH sensitivity, are low in
males at this age [59]. Therefore, high gonadotropins in
15-day-old castrated males may be the consequence of a
combination of acquired female characteristics plus an
increased GnRH secretion due to castration. Thus, these
hormonal changes indicate effectiveness of treatments. In
addition, these results suggest that while neonatal castra-
tion is successful in demasculinizing and feminizing the
control of gonadotropin secretion, it is insufficient to
modify GABABR expression. It is interesting to note that
neonatally castrated males showed measurable levels of
testosterone, probably of adrenal origin [60, 61], in agree-
ment with previous reports [62]. Furthermore, 100 Ìg TP-
treated females were effectively masculinized in their
gonadotropin secretion patterns and testosterone levels as
well as GABABR expression.
While these experiments conveyed the idea that
GABABR expression is under steroid hormone control at
early stages of development, some uncertainties emerged
from our results. Was castration insufficient to modify
GABABR expression in males because intrauterine testos-
terone imprinting had already occurred in these animals?
Was the testosterone effect in females due to neonatal
masculinization of GABABR expression or to high circu-
lating androgens, still present at the time of sampling?
To answer these questions a new set of experiments
was designed in 8-day-old animals.
In addition to neonatal castration, in a group of males
the effect of intrauterine testosterone (first androgenizing
peak) was abolished by treatment of pregnant rats with
Flut, a non-steroidal anti-androgen which blocks T and
DHT action [29, 49, 63]. Moreover, a third group of males
was exposed to embryonic Flut treatment and castrated at
birth to abolish both masculinizing peaks. With regards to
females, in addition to the 100 Ìg TP androgenization
protocol, a second low-dose androgenization scheme was
undertaken [42].
Males treated with Flut showed a significant increase
in GABAB(1) expression when compared to controls. In
neonatally castrated Flut-treated males, GABABR sub-
unit expression was even higher. The anti-androgen also
blocked masculinization of various androgen-dependent
anatomical characteristics (e.g. external genitalia). Flut
did not modify gonadotropins or GABABR expression in
females, as was to be expected. These results clearly dem-
onstrate that testosterone and/or its metabolites [64, 65]
play crucial roles in determining pituitary GABABR sub-
unit expression at early stages of development, both
androgenizing peaks being involved, though the intrauter-
ine one appears to be the most critical. The fact that Flut
completely reverted the male GABABR expression pat-
tern to a female pattern suggests that the androgen recep-
tor is selectively important in the sexual differentiation of
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
5/
20
17
 9
:0
9:
04
 A
M
140 Neuroendocrinology 2004;80:129–142 Bianchi/Catalano/Bonaventura/Silveyra/
Bettler/Libertun/Lux-Lantos
the pituitary, at least regarding the parameter analyzed
here. This hypothesis is supported by the results obtained
by neonatal testosterone treatment in females.
On the other hand, females treated with the low dose
androgenization protocol showed no alterations in
GABABR expression or in gonadotropins. Testosterone
was high in these animals, similar to control males and to
100-Ìg TP-treated females, suggesting that the effect ob-
served in GABABR expression in the 100-Ìg TP group
was not due to testosterone presence at the time of sam-
pling. Though this low dose androgenizing protocol did
not modify GABABR expression, it profoundly altered the
hypothalamic-pituitary-ovarian axis; these animals pre-
sented early vaginal opening in an atypical way (pinhole,
as reported previously [42]), elevated FSH and lack of
cycling or gonadotropin surges in adulthood. In addition,
alterations in uterine horns and ovarian volume were also
observed at autopsy.
Results from the androgenization protocols suggest
that while both were effective in altering gonadotropin
secretion in adulthood, a certain dose of testosterone is
needed to masculinize GABABR expression. It has been
proposed that different structures, tissues, characteristics
may display differential susceptibility to androgen action,
requiring different doses for effects to be observed [42, 66,
67]. Interestingly, sex steroid modulation of GABABR
expression in several CNS areas has also been suggested in
cycling rats [68].
The evidence of steroid-dependent sexual differences
in GABABR expression is not an isolated observation,
since the participation of GABA and its receptors has
been proposed to play key roles in sexual differentiation
of the brain and in sexually dimorphic hormone secretion
patterns [69–72].
As GABA had been shown to modulate the expression
of its own receptors in the CNS [47], we evaluated GABA
and other neurotransmitters in the hypothalami of 8-day-
old animals in the different treatment groups. Interesting-
ly, only hypothalamic GABA levels showed the same pat-
tern as pituitary GABABR expression, this neurotransmit-
ter being higher in females than in males, and modulated
by steroid manipulation in the same way. Though in gen-
eral testosterone was proposed to increase GABA levels
[68, 72], in some areas as the amygdala and the medial
septal nucleus castration was shown to induce an increase
in this neurotransmitter [73], similar to our data. Our
present in vivo results cannot discriminate whether an-
drogen action on pituitary GABABR expression and hy-
pothalamic GABA levels are parallel responses to the
same stimulus or one is the consequence of the other. In
vitro experiments have already been undertaken to dis-
criminate between these possibilities.
In conclusion, these data demonstrate that testosterone
plays a role in modulating sexually dimorphic pituitary
GABABR expression and hypothalamic GABA levels at
early stages of development. Prenatal exposure of males
to androgens determines postnatal pituitary GABAB1R
expression, while increased neonatal TP can decrease
GABAB1R expression levels normally found in females.
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